Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar 15;66(3):e0224221.
doi: 10.1128/aac.02242-21. Epub 2022 Jan 10.

Antifungal Resistance Trends of Candida auris Clinical Isolates in New York and New Jersey from 2016 to 2020

Shannon Kilburn  1 , Gabriel Innes  2 , Monica Quinn  1 , Karen Southwick  3 , Belinda Ostrowsky  4 , Jane A Greenko  5 , Emily Lutterloh  1   6 , Rebecca Greeley  2 , Reed Magleby  2 , Vishnu Chaturvedi  1 , Sudha Chaturvedi  1   6
Affiliations

Antifungal Resistance Trends of Candida auris Clinical Isolates in New York and New Jersey from 2016 to 2020

Shannon Kilburn et al. Antimicrob Agents Chemother. .

Abstract

About 55% of U.S. Candida auris clinical cases were reported from New York and New Jersey from 2016 through 2020. Nearly all New York-New Jersey clinical isolates (99.8%) were fluconazole resistant, and 50% were amphotericin B resistant. Echinocandin resistance increased from 0% to 4% and pan-resistance increased from 0 to <1% for New York C. auris clinical isolates but not for New Jersey, highlighting the regional differences.

Keywords: Candida auris; antifungals; epidemiological cutoff; minimum inhibitory concentration.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

FIG 1
FIG 1
Antifungal susceptibility pattern of C. auris clinical isolates from New York, 2016 to 2020. (A) Percent C. auris resistant isolates to antifungals for which CDC tentative MIC breakpoint (CDC-BP) are available. Most of the isolates were resistant to fluconazole (FLC) followed by amphotericin B (AMB), with a small number exhibiting resistance to echinocandins. (B) Percent C. auris non-wild-type isolates based on epidemiological cutoff values (ECV). A higher percentage of C. auris isolates were non-wild-type to posaconazole (POS) compared with the other azoles and 5-flucytosine (5-FC).
FIG 2
FIG 2
Antifungal susceptibility pattern of C. auris clinical isolates from New Jersey, 2017 to 2020. (A) Percent C. auris resistant isolates to antifungals for which CDC tentative MIC breakpoint (CDC-BP) are available. All isolates were resistant to fluconazole (FLC) followed by amphotericin B (AMB), while none showed resistance to echinocandins. (B) Percent C. auris non-wild-type isolates based on epidemiological cutoff values (ECV). A higher percentage of C. auris isolates was non-wild-type to posaconazole (POS) compared with the other azoles.
See this image and copyright information in PMC

References

    1. Anonymous. 2019. Antibiotic resistance threats in the United States, 2019. Centers for Disease Control and Prevention, Atlanta, GA. 10.15620/cdc:82532. - DOI
    1. Vallabhaneni S, Kallen A, Tsay S, Chow N, Welsh R, Kerins J, Kemble SK, Pacilli M, Black SR, Landon E. 2016. Investigation of the first seven reported cases of Candida auris, a globally emerging invasive, multidrug-resistant fungus—United States, May 2013–August 2016. Morbidity and Mortality Wkly Report 65:1234–1237. 10.15585/mmwr.mm6544e1. - DOI - PubMed
    1. Anonymous. 2021. Tracking Candida auris, on Centers for Disease Control and Prevention. https://www.cdc.gov/fungal/candida-auris/tracking-c-auris.html. Accessed March 24, 2021.
    1. Adams E, Quinn M, Tsay S, Poirot E, Chaturvedi S, Southwick K, Greenko J, Fernandez R, Kallen A, Vallabhaneni S, Haley V, Hutton B, Blog D, Lutterloh E, ZuckCer H. 2018. Candida auris in healthcare facilities, New York, USA, 2013–2017. Emerg Infect Dis 24:1816–1824. 10.3201/eid2410.180649. - DOI - PMC - PubMed
    1. Lockhart SR, Etienne KA, Vallabhaneni S, Farooqi J, Chowdhary A, Govender NP, Colombo AL, Calvo B, Cuomo CA, Desjardins CA, Berkow EL, Castanheira M, Magobo RE, Jabeen K, Asghar RJ, Meis JF, Jackson B, Chiller T, Litvintseva AP. 2017. Simultaneous emergence of multidrug-resistant Candida auris on 3 continents confirmed by whole-genome sequencing and epidemiological analyses. Clin Infect Dis 64:134–140. 10.1093/cid/ciw691. - DOI - PMC - PubMed

Publication types

Substances

LinkOut - more resources